Literature DB >> 11531956

Prevention of adjuvant arthritis by the W3/25 anti-CD4 monoclonal antibody is associated with a decrease of blood CD4(+)CD45RC(high) T cells.

C Pelegrí1, M Castell, M Serra, M Rabanal, M Rodríguez-Palmero, C Castellote, A Franch.   

Abstract

Imbalance between Th1 and Th2 functions is considered to play a key role in the induction and development of several autoimmune diseases, and the correction of that imbalance has led to effective therapies of some experimental pathologies. To examine whether CD4(+)CD45RC(high) (Th1-like) and CD4(+)CD45RC(low) (Th2-like) lymphocytes play a role in the pathogenesis of adjuvant arthritis (AA) and in its prevention by anti-CD4 antibody, CD45RC expression on CD4(+) T cells was determined in arthritic rats and in animals treated with an anti-CD4 MoAb (W3/25) during the latency period of AA. The phenotype of regional lymph node lymphocytes from arthritic rats in the active phase of the disease was determined by flow cytometry. Peripheral blood lymphocytes from rats treated with W3/25 MoAb were also analysed for 2 weeks after immunotherapy finished. IgG2a and IgG1 isotypes of sera antibodies against the AA-inducing mycobacteria, considered to be associated with Th1 and Th2 responses, respectively, were also determined by ELISA techniques. Fourteen days after arthritis induction, regional lymph nodes presented an increase in CD4+CD45RC(high) T cell proportion. Preventive immunotherapy with W3/25 MoAb inhibited the external signs of arthritis and produced a specific decrease in blood CD4(+)CD45RC(high) T cells and a diminution of antibodies against mycobacteria, more marked for IgG2a than for IgG1 isotype. These results indicate a possible role of CD4(+)CD45RC(high) T lymphocytes in the pathogenesis of AA, and suggest that the success of anti-CD4 treatment is due to a specific effect on CD4(+)CD45RC(high) T subset that could be associated with a decrease in Th1 activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11531956      PMCID: PMC1906151          DOI: 10.1046/j.1365-2249.2001.01592.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

Review 1.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

Review 2.  T-cell memory: the connection between function, phenotype and migration pathways.

Authors:  C R Mackay
Journal:  Immunol Today       Date:  1991-06

3.  Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis.

Authors:  R J Dolhain; A N van der Heiden; N T ter Haar; F C Breedveld; A M Miltenburg
Journal:  Arthritis Rheum       Date:  1996-12

4.  CD4 mAb therapy modulates alloantibody production and intracardiac graft deposition in association with selective inhibition of Th1 lymphokines.

Authors:  J W Kupiec-Weglinski; B Wasowska; I Papp; G Schmidbauer; M H Sayegh; W M Baldwin; K J Wieder; W W Hancock
Journal:  J Immunol       Date:  1993-11-01       Impact factor: 5.422

5.  MRC OX-19: a monoclonal antibody that labels rat T lymphocytes and augments in vitro proliferative responses.

Authors:  M J Dallman; M L Thomas; J R Green
Journal:  Eur J Immunol       Date:  1984-03       Impact factor: 5.532

6.  The thymus contains a high frequency of cells that prevent autoimmune diabetes on transfer into prediabetic recipients.

Authors:  A Saoudi; B Seddon; D Fowell; D Mason
Journal:  J Exp Med       Date:  1996-12-01       Impact factor: 14.307

7.  Treatment with a chimeric CD4 monoclonal antibody is associated with a relative loss of CD4+/CD45RA+ cells in patients with rheumatoid arthritis.

Authors:  P A van der Lubbe; F C Breedveld; P P Tak; A Schantz; J Woody; A M Miltenburg
Journal:  J Autoimmun       Date:  1997-02       Impact factor: 7.094

8.  Cellular and molecular mechanism for Kilham rat virus-induced autoimmune diabetes in DR-BB rats.

Authors:  Y H Chung; H S Jun; M Son; M Bao; H Y Bae; Y Kang; J W Yoon
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

9.  T-lymphocyte heterogeneity in the rat: separation of functional subpopulations using a monoclonal antibody.

Authors:  R A White; D W Mason; A F Williams; G Galfre; C Milstein
Journal:  J Exp Med       Date:  1978-09-01       Impact factor: 14.307

10.  MRC OX-22, a monoclonal antibody that labels a new subset of T lymphocytes and reacts with the high molecular weight form of the leukocyte-common antigen.

Authors:  G P Spickett; M R Brandon; D W Mason; A F Williams; G R Woollett
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

View more
  5 in total

Review 1.  Biological therapies directed against cells in autoimmune disease.

Authors:  Paul Hasler
Journal:  Springer Semin Immunopathol       Date:  2006-04-28

2.  Anti-CD4 monoclonal antibody treatment in acute and early chronic antigen-induced arthritis: influence on T helper cell activation.

Authors:  D Pohlers; K Nissler; O Frey; J Simon; P K Petrow; R W Kinne; R Bräuer
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

3.  New rat model of Pneumocystis pneumonia induced by anti-CD4(+) T-lymphocyte antibodies.

Authors:  Timothy D Thullen; Alan D Ashbaugh; Kieran R Daly; Michael J Linke; Paul E Steele; Peter D Walzer
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

4.  Immune activation is required for NT-3-induced axonal plasticity in chronic spinal cord injury.

Authors:  Qin Chen; George M Smith; H David Shine
Journal:  Exp Neurol       Date:  2007-12-07       Impact factor: 5.330

5.  Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis.

Authors:  Rebecca Anderson; Angels Franch; Margarida Castell; Francisco J Perez-Cano; Rolf Bräuer; Dirk Pohlers; Mieczyslaw Gajda; Alexandros P Siskos; Theodora Katsila; Constantin Tamvakopoulos; Una Rauchhaus; Steffen Panzner; Raimund W Kinne
Journal:  Arthritis Res Ther       Date:  2010-07-19       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.